Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Why 10-DAB Matters in Taxane Chemistry
2026-11-20
10-DAB is best interpreted as a structurally important taxane intermediate, not as a direct measure of anticancer activity. Its value arises from the preserved taxane framework, the documented C13 hydroxyl–C4 acetyl relationship, and its role in preparing taxol and related derivatives.
Interpreting KIX–KID Inhibition in Cell Systems
2026-11-20
NSC228155 is reported to inhibit the CREB–CBP KIX–KID interaction more potently in a biochemical assay than it inhibits transcriptional readouts in living cells. Comparing these measurements clarifies what the compound supports mechanistically, while also showing why cellular activity cannot be interpreted as a direct measure of interaction affinity.
What Do Columbin’s Activity Values Mean?
2026-11-19
Columbin is described as a diterpene furanolide associated with inflammation modulation research and anti-trypanosomal drug development. Its reported IC50 of 53.1 μM and EC-related value of 327 μM are assay-dependent signals, not standalone evidence of a defined molecular target, organism-level efficacy, or clinical benefit.
How MMAF Potency Relates to Cell Viability
2026-11-19
MMAF is an auristatin F-derived microtubule polymerization inhibitor whose low-nanogram-per-milliliter viability values in selected tumor-cell models indicate potent assay-context cytotoxicity. Those results clarify payload activity, but they do not independently establish ADC selectivity, tolerability, or clinical benefit.
How Should a CFTR Ki Be Interpreted?
2026-11-18
GlyH-101 is documented as a cell-permeable glycinyl hydrazone that blocks CFTR, with a reported Ki of 1.4 μM. Interpreting that value requires separating molecular inhibition from channel-current measurements and downstream epithelial effects.
When Context Changes a Laurdan Readout
2026-11-18
Laurdan generalized polarization reports membrane hydration and lipid packing, but its meaning depends on the membrane model, comparator and downstream endpoint. A study of kinetically programmed PEG shedding illustrates why an upstream physical-state signal cannot, by itself, establish nanoparticle uptake, mRNA expression or therapeutic efficacy.
(R)-MG132 and the Limits of Mechanistic Controls
2026-11-17
A critical comparison of evidence linking HNRNPU K181 lactylation to PHGDH regulation in cervical cancer, and the separate role of (R)-MG132 as a stereochemistry-based proteasome control. The available study supports a lactate–HNRNPU–PHGDH axis, but does not establish that proteasome inhibition or proteasome dependence explains the reported phenotype.
How to Interpret Actein Cancer Readouts
2026-11-17
Actein is described as a triterpene glycoside associated with reduced cell proliferation and changes in autophagy and apoptosis in human bladder cancer research. These findings operate at different biological levels, so they support a mechanistic hypothesis rather than a complete anticancer mechanism or a conclusion about human safety.
How Cullin3 Neddylation Shapes NRF2
2026-11-16
DI-1859 is described as a selective covalent inhibitor of cullin3 neddylation. The documented pathway links reduced CRL3 activity with increased NRF2 protein in mouse liver and reported protection in an acetaminophen-induced liver-injury model, while the available evidence remains limited to product-level claims and does not establish clinical relevance.
SIRT1, Type H Vessels, and Bone Repair
2026-11-16
Research in aged mice and senescent bone and endothelial cell models links reduced SIRT1 activity with impaired vascular–osteogenic coordination. The findings support a model in which SIRT1 influences β-catenin/Wnt signaling and reciprocal paracrine communication, while leaving important questions about pharmacological specificity, causality, and translation to human osteoporosis.
What Does Nedaplatin’s Colony IC50 Mean?
2026-11-15
A tumor colony-forming IC50 connects Nedaplatin’s reported DNA-damage activity with a population-level measure of reproductive survival. The value of 94 μM is assay-specific potency evidence, not a direct measure of DNA lesions, clinical effectiveness, or universal activity across tumor models.
How Sulfapyridine Produces an Antibacterial Signal
2026-11-14
Sulfapyridine is identified as a sulfonamide antibacterial. Its class-level mechanism links competition with bacterial folate synthesis to downstream changes in metabolic activity and growth, while the identity record alone cannot establish a product-specific potency or performance result.
How PGAM5 Inhibition May Protect the BBB
2026-11-13
LFHP-1c is described as an inhibitor of endothelial PGAM5 with reported protective effects on blood–brain barrier integrity during ischemic injury. The documented mechanism connects PGAM5 binding and altered NRF2 interaction with cellular stress signaling, but the direction and completeness of that pathway remain uncertain.
How Should Adrenosterone’s Weak Signal Be Read?
2026-11-13
A weak androgenic effect is a qualitative biological description, not a potency value or proof of a defined receptor mechanism. This article separates Adrenosterone’s molecular identity from steroid hormone signaling, hormone metabolism, and the cellular readouts used in endocrinology research.
How T7 Transcription Becomes an RNAi Input
2026-11-12
A mechanism-based explanation of what T7-driven dsRNA synthesis establishes, how nuclease and cleanup components affect material interpretation, and why RNA production does not by itself demonstrate delivery or gene-silencing efficacy.